SM08502-Mediated β-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression
Journal Article
Overview
publication date
- December 1, 2025
has subject area
- Adnexal Diseases - Ovarian Neoplasms
- Animals
- Antineoplastic Agents - Poly(ADP-ribose) Polymerase Inhibitors
- Armadillo Domain Proteins - beta Catenin
- Biochemical Phenomena - Wnt Signaling Pathway
- Catenins - beta Catenin
- Cell Line - Cell Line, Tumor
- Cell Physiological Phenomena - Wnt Signaling Pathway
- Disease Progression
- Drug Resistance, Neoplasm
- Drug Synergism
- Drug Therapy - Antineoplastic Combined Chemotherapy Protocols
- Drug Therapy, Combination - Antineoplastic Combined Chemotherapy Protocols
- Endocrine System Diseases - Ovarian Neoplasms
- Enzyme Inhibitors - Poly(ADP-ribose) Polymerase Inhibitors
- Female
- Female Urogenital Diseases - Ovarian Neoplasms
- Gene Expression Regulation, Neoplastic
- Gonadal Disorders - Ovarian Neoplasms
- Humans
- Investigative Techniques - Xenograft Model Antitumor Assays
- Mice
- Neoplasm Transplantation - Xenograft Model Antitumor Assays
- Neoplasms by Site - Ovarian Neoplasms
- Phthalazines
- Piperazines
- Therapeutics - Antineoplastic Combined Chemotherapy Protocols
- Transcription Factors - beta Catenin
- Tumor Cells, Cultured - Cell Line, Tumor
Date in CU Experts
- December 10, 2025 10:07 AM
Full Author List
- Corr BR; Woodruff ER; Yamamoto TM; Jordan KR; Danhorn T; Bossard C; Nguyen LL; Chuong EB; Wick L; Young A
author count
- 14
citation count
- 1
published in
- Cancer Research Communications Journal
Other Profiles
Electronic International Standard Serial Number (EISSN)
- 2767-9764
Digital Object Identifier (DOI)
Additional Document Info
start page
- 2112
end page
- 2126
volume
- 5
issue
- 12